Tagrisso
Payments companies reported to CMS as associated with Tagrisso. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Tagrisso, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Tagrisso
These are the largest totals companies reported as associated with Tagrisso. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jeffrey Gregg | Sacramento, CA | $200,809.55 | |
| Hatim Husain | San Diego, CA | Internal Medicine | $170,174.60 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $123,243.19 |
| Beth Sandy | Philadelphia, PA | Adult Health (Nurse Practitioner) | $110,708.10 |
| Noam Drazin | Beverly Hills, CA | Medical Oncology | $104,227.23 |
| Mark Socinski | Orlando, FL | Hematology & Oncology | $101,700.59 |
| Ani Balmanoukian | Baltimore, MD | Hematology & Oncology | $75,903.17 |
| Tarek Mekhail | Orlando, FL | Hematology & Oncology | $69,516.83 |
| Gustavo Cumbo Nacheli | Grand Rapids, MI | Pulmonary Disease | $67,287.65 |
| Bobby Chawla | Caldwell, ID | Hematology & Oncology | $61,582.96 |
Prescribed Tagrisso?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.